RxDoctor Payments Data

Raymond Paul Blanc, MD

Urology · Mansfield, MANPI 1831197748

Payments from drug & device makers

$7,791in general payments, 2019–2025

Across 103 payments — averaging $75.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • Teleflex LLC$2K
  • Neotract Inc.$1K
  • Dentsply IH Inc.$267
  • Astellas Pharma US Inc$150
  • Sumitomo Pharma America, Inc.$145
  • plus $1K from 18 others

What the payments were for

  • Consulting fees$1402%
  • Travel & lodging$5,15066%
  • Food & beverage$2,39531%
  • Education$1061%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,791 in reported general payments places this provider in the 75th percentile of 327 urology providers in Massachusetts.

See all urology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$201,917
Medicare patients
669
Services billed
1,907

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron27$25,649
MyrbetriqMirabegron29$16,373
Testosterone59$8,963
Tamsulosin Hcl656$8,465
Alfuzosin Hcl ErAlfuzosin Hcl277$6,480
Finasteride414$5,091
Potassium Citrate ErPotassium Citrate43$4,898
Tadalafil17$1,564
NitrofurantoinNitrofurantoin Macrocrystal71$1,494
Tolterodine Tartrate ErTolterodine Tartrate19$1,302
Dutasteride38$1,251
Solifenacin Succinate17$1,080
Bicalutamide31$1,044
Oxybutynin Chloride ErOxybutynin Chloride37$943
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst77$868

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$145$25,64927 claims
Astellas Pharma US IncMyrbetriq$150$16,37329 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 327 urology providers in Massachusetts.

Other urology in Mansfield

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →